A number of European countries (including Ireland, France, the Netherlands, Sweden and the United Kingdom) indicate an increase seen during 2022, particularly since September 2022, in the number of cases of invasive Group A Streptococcus (iGAS) disease among children less than ten years of age.
On the occasion of the tenth anniversary of European Immunization Week, ECDC is releasing a new complement of data, tools, blogs and updates to support public health authorities in their work against vaccine preventable diseases.
Recent evidence on use of HPV vaccines in boys and men and on the efficacy of a two dose schedule may warrant to significant policy changes in the near future.
The study design and analysis controlled for influence of potentially confounding trends, such as improvement of day-care carriage and decreasing prevalence of smoking during the study period.
Today, ECDC publishes an update to its 2008 Guidance on human papillomavirus (HPV) vaccines in Europe. The update follows the introduction of vaccination programmes in 19 European countries and new evidence from research studies over the past four years.
The study compares the incidence and serotype distribution of invasive pneumococcal disease (IPD) for pneumococcal meningitis and non-meningitis IPD in children from 2007 to 2010 with reference to the pre-vaccination period from 1997 to 2001 in Germany.
HPV DNA detection in urine is a feasible practice and a useful tool in future research; however, the available studies dealing on the topic appear too diverse in their setup and applied methodology to draw conclusive statements
This study found a marked reduction in vaccine serotype carriage after PCV7 implementation. The overall pneumococcal, H. influenzae and S. aureus carriage decreased slightly, but not significantly.